Data from the phase 3 MSB-GVHD001 trial support the FDA approval of remestemcel-L in pediatric SR-aGVHD.
Approval Alert | Remestemcel-L in Pediatric Steroid-Refractory Acute GVHD
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will RLTs Be Integrated Into the Prostate Cancer Treatment Paradigm?
2
Casdatifan Monotherapy Achieves Clinical Activity in Late-Line Kidney Cancer
3
Dato-DXd Improves Survival in Recurrent Inoperable/Metastatic TNBC
4
Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors
5
